Marksans Pharma Ltd
Marksans Pharma Q2 Results 2026 (FY27): Revenue ₹958.3 Cr, PAT ₹143.5 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #68 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Marksans Pharma Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Total Income: ₹958.3 crore (29.2% YoY growth).
As stated in Marksans Pharma Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Marksans Pharma Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Total Income: ₹958.3 crore (29.2% YoY growth). Q2FY27 EBITDA: ₹214.3 crore, up 48.3% YoY (from ₹144.5 crore in Q2FY26).
From Marksans Pharma Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Marksans Pharma's revenue grow in the September 2026 quarter?
- Q2FY27 Total Income: ₹958.3 crore (29.2% YoY growth)
- Q2FY27 Operating Revenue: ₹940.2 crore (30.5% YoY growth)
- Q2FY27 consolidated revenue highlights:
- UK & Europe: ₹405 crore, +64.9% YoY
- US & North America: ₹421 crore, +8.7% YoY
- Australia & New Zealand: ₹101 crore, +44.8% YoY
- Rest of World: ₹14 crore, -47.0% YoY (impact from West Asia crisis)
- H1FY27 Operating Revenue: ₹1,781 crore, +32.9% YoY
2 more points from Marksans Pharma Ltd's call on revenue
Create a free account to keep reading this call
What happened to Marksans Pharma's margins in Q2 FY27?
See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.
What capex is Marksans Pharma planning?
- Capex of ₹46 crore in H1FY27 (Page 36)
- India manufacturing capacity target: 16 billion units per annum (FY27 and beyond) (Page 40)
- Acquired Goa facility with scalable capacity of 8 billion units p.a., doubling India output (Pages 27, 39)
- Expansion plans include tablets, hard capsules, ointments, liquids, creams manufacturing (Page 32)
2 more points from Marksans Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Marksans Pharma raising money or cutting debt?
See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Marksans Pharma's order book?
See what Marksans Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Marksans Pharma Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹841 Cr, net profit ₹159 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Marksans Pharma Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY . Key investor presentation takeaways from Biocon Ltd's Q2 FY27 investor presentation — and how it ranks a
- Alembic Pharma (Q2 FY27)
Total Revenue for Q2 FY27: ₹26.03 billion, up 36% YoY (Page 12, Page 4) . Key investor presentation takeaways from Alembic Pharmaceuticals Ltd's Q2 FY27 investo
- Zydus Lifesciences (Q2 FY27)
79,096 mn, up 29.2% YoY (Page 14) . Key investor presentation takeaways from Zydus Lifesciences Ltd's Q2 FY27 investor presentation — and how it ranks against s
- Lupin (Q2 FY27)
Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13) . Key investor presentation takeaways from Lupin Ltd's Q2 FY27 investor presentation — and how it ran
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Marksans Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Marksans Pharma Ltd Q2 FY27 results?
Q2FY27 Total Income: ₹958.3 crore (29.2% YoY growth). Q2FY27 EBITDA: ₹214.3 crore, up 48.3% YoY (from ₹144.5 crore in Q2FY26).
What is Marksans Pharma Ltd share price analysis?
Marksans Pharma Ltd currently shows a neutral. The stock trades at a P/E of 27.7 with a market cap of ₹14,288 Cr. Investors should review the full earnings analysis for detailed insights.
Is Marksans Pharma Ltd planning capital expenditure?
Capex of ₹46 crore in H1FY27 (Page 36).
Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.